Federation of Clinical Immunology Societies (FOCIS) Annual Meeting


Tuesday, June 18, 2019 - Friday, June 21, 2019


Boston, MA
Attendees of the Federation of Clinical Immunology Societies (FOCIS) Annual Meeting


Charles River is pleased to participate in the scientific program at the Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS).

With deep knowledge of the immune system that spans its role in infection and autoimmune disease -- as well as in those diseases not traditionally considered immunogenic, such as neurodegeneration, metabolic and cardiovascular diseases, and even cancer -- Charles River's team of immunologists, biologists and chemists have put together a wide array of scientific posters to share the latest advances in this important field.

Visit Booth 12 to learn how our expertise in immunology makes us the ideal partner for any program targeting immune mediated disease, and discover how our integrated immunology portfolio, including in vitro assays, translational biomarkers, and modalities can take you from discovery to the clinic.

Request a meeting

Scientific Posters

Location: Boston Marriott Copley Place, Salon E, Fourth Floor
Tuesday June 18 6:15-7:30 PM 

  • T97 | A Translational Platform to Support and Advance Immuno-Oncology Drug Discovery | Jeroen De Groot, PhD
  • T99 | Analysis of Molecular and Cellular Responses Associated with Immune Checkpoint Inhibition in the MC38 Colon Carcinoma Model | David Harris, PhD
  • T104 | Building a Translational Pathway Using Human Myeloid Cell Assays to Enable Development of Cancer Immune Therapies | Louise Brackenbury, PhD
  • T105 | Building a Translational Pathway Using Pharmacodynamic Models to Enable the Development of Cancer Immune Therapies | Rhiannon Jenkinson, PhD
  • T109 | Deciphering the Role of the Tumor Infiltrating Lymphocytes in Anti-Angiogenic Therapy Using a Humanized PDX In Vivo Platform | Julia Schueler, PhD
  • T43 | Inclusion of Exploratory PD Biomarkers in First-in-human Clinical Trials Adds Value by Providing Information to Confirm the Mode of Action of a Candidate Therapeutic | Rhiannon Jenkinson, PhD
  • T44 | LPS-induced Neuroinflammation Assay Combination for Development of New Treatment Strategies | Gunnar Flik, PhD
  • T50 | Th17-derived Cytokines Might be Involved in the Allergic Contact Dermatitis Induced by Poison Ivy Active Ingredient, Urushiol | Rana Samadfam, PhD
  • T133 | Two In Vitro Assays for Evaluating the Potency and Efficacy of Prospective Drugs in Multiple Diseases Involving Both Classically and Alternative Activated Macrophages | Sanne Demandt, PhD

Wednesday June 19 6:15-7:30 PM

  • W104 | Profiling of 1,600 Novel Natural Product-based Compounds in Human Primary Cell-based Phenotypic Assays | Jamil Aarbiou, PhD

Thursday June 20, 6:15-7:30 PM

  • H119 | Modelling Inflammatory Bowel Disease using a Translational Assay Platform | Louise Brackenbury, PhD
  • W47 | Development of Chemotaxis Assays for Human Blood-Derived Neutrophils and Monocytes Suitable for the Identification and Validation of Potential Drug Targets | Lisa Scandiuzzi, PhD 
  • H117 | Evaluation of Different Lactobacillus Strains on the Treatment of Inflammatory Bowel Disease in a Murine Model | Rana Samadfam, PhD